Xiyu Shang, Yuqing Cao, Yang Guo, Lei Zhang, Jiajia Li, Huifang Zhang, Yipin Fan, Yuxuan Huang, Jiantao Li, Yanping Wang, Yibai Xiong, Qiujie Cai, Huamin Zhang, Yan Ma
{"title":"Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.","authors":"Xiyu Shang, Yuqing Cao, Yang Guo, Lei Zhang, Jiajia Li, Huifang Zhang, Yipin Fan, Yuxuan Huang, Jiantao Li, Yanping Wang, Yibai Xiong, Qiujie Cai, Huamin Zhang, Yan Ma","doi":"10.1186/s40249-024-01263-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Traditional Chinese medicine (TCM) has developed a rich theoretical system and practical experience in fighting to infectious diseases over the past thousands of years, and has played an important role in controlling the spread owing to its unique advantages. In particular, its significant contribution to the prevention and control of Corona Virus Disease 2019 (COVID-19) is widely recognized. COVID-19 infection is mainly non-severe with a favorable overall outcome, but patients with comorbidities tend to have a poor prognosis. However, a comprehensive review of TCM for preventing and treating COVID-19 with comorbidities across various systems is still lacking. Hence, this scoping review aims to conduct a comprehensive investigation on treatment outcome of TCM for treating COVID-19 with comorbidities across various systems.</p><p><strong>Methods: </strong>The scoping review was conducted by searching English databases including PubMed and Web of Science, and Chinese databases including China National Knowledge Infrastructure and Wanfang between January 2020 and January 2024. We followed the inclusion and exclusion criteria to identify relevant literature. Information for inclusion in the literature were subsequently extracted and consolidated.</p><p><strong>Results: </strong>We enrolled 13 literature that met the inclusion criteria in the review finally. Our analysis revealed that research on COVID-19 with comorbidities was mostly focused on circulatory diseases, including hypertension, heart failure, and cerebrovascular diseases, most common comorbidities were hypertension. Followed by endocrine and metabolic diseases such as diabetes, respiratory diseases including pulmonary tuberculosis and chronic obstructive pulmonary disease have been also addressed. However, there were few studies on co-infectious urogenital system disease, and no studies on the rheumatic, immune, hematological, nervous, reproductive, and skin systems diseases. Based on existing studies, TCM has significantly improved the clinical symptoms of COVID-19 with comorbidities such as fever, fatigue, dry cough, anorexia and asthma, the absorption of lung lesions, shortened the duration of viral shedding and the course of disease.</p><p><strong>Conclusions: </strong>TCM has great application prospects in treating COVID-19 with comorbidities. These findings could provide important evidence for clinicians to treat COVID-19 with comorbidities. Multi-center studies are required to confirm our results in the future.</p>","PeriodicalId":48820,"journal":{"name":"Infectious Diseases of Poverty","volume":"13 1","pages":"97"},"PeriodicalIF":8.1000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658301/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases of Poverty","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40249-024-01263-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Traditional Chinese medicine (TCM) has developed a rich theoretical system and practical experience in fighting to infectious diseases over the past thousands of years, and has played an important role in controlling the spread owing to its unique advantages. In particular, its significant contribution to the prevention and control of Corona Virus Disease 2019 (COVID-19) is widely recognized. COVID-19 infection is mainly non-severe with a favorable overall outcome, but patients with comorbidities tend to have a poor prognosis. However, a comprehensive review of TCM for preventing and treating COVID-19 with comorbidities across various systems is still lacking. Hence, this scoping review aims to conduct a comprehensive investigation on treatment outcome of TCM for treating COVID-19 with comorbidities across various systems.
Methods: The scoping review was conducted by searching English databases including PubMed and Web of Science, and Chinese databases including China National Knowledge Infrastructure and Wanfang between January 2020 and January 2024. We followed the inclusion and exclusion criteria to identify relevant literature. Information for inclusion in the literature were subsequently extracted and consolidated.
Results: We enrolled 13 literature that met the inclusion criteria in the review finally. Our analysis revealed that research on COVID-19 with comorbidities was mostly focused on circulatory diseases, including hypertension, heart failure, and cerebrovascular diseases, most common comorbidities were hypertension. Followed by endocrine and metabolic diseases such as diabetes, respiratory diseases including pulmonary tuberculosis and chronic obstructive pulmonary disease have been also addressed. However, there were few studies on co-infectious urogenital system disease, and no studies on the rheumatic, immune, hematological, nervous, reproductive, and skin systems diseases. Based on existing studies, TCM has significantly improved the clinical symptoms of COVID-19 with comorbidities such as fever, fatigue, dry cough, anorexia and asthma, the absorption of lung lesions, shortened the duration of viral shedding and the course of disease.
Conclusions: TCM has great application prospects in treating COVID-19 with comorbidities. These findings could provide important evidence for clinicians to treat COVID-19 with comorbidities. Multi-center studies are required to confirm our results in the future.
背景:几千年来,中医在与传染病的斗争中积累了丰富的理论体系和实践经验,并以其独特的优势在控制传染病传播方面发挥了重要作用。特别是,它对预防和控制2019冠状病毒病(COVID-19)的重要贡献得到了广泛认可。COVID-19感染主要是非严重的,总体预后良好,但有合并症的患者往往预后较差。然而,中医药在不同系统中防治新冠肺炎合并症的综合综述仍然缺乏。因此,本综述旨在对不同系统的中医药治疗新冠肺炎合并症的疗效进行全面调查。方法:检索PubMed、Web of Science等英文数据库和中国知网、万方等中文数据库,检索时间为2020年1月至2024年1月。我们按照纳入和排除标准来确定相关文献。随后摘录和合并了列入文献的资料。结果:最终纳入13篇符合纳入标准的文献。我们的分析显示,关于COVID-19合并合并症的研究主要集中在循环系统疾病,包括高血压、心力衰竭和脑血管疾病,最常见的合并症是高血压。其次是内分泌和代谢疾病,如糖尿病,呼吸系统疾病,包括肺结核和慢性阻塞性肺病也已得到处理。然而,对泌尿生殖系统共感染性疾病的研究较少,对风湿病、免疫系统、血液系统、神经系统、生殖系统和皮肤系统疾病的研究较少。从现有研究来看,中医药能显著改善新冠肺炎合并发热、乏力、干咳、厌食、哮喘等临床症状,促进肺部病变的吸收,缩短病毒的排出时间和病程。结论:中医药治疗新冠肺炎合并症具有广阔的应用前景。这些发现可为临床医生治疗伴有合并症的COVID-19提供重要证据。未来需要多中心研究来证实我们的结果。
期刊介绍:
Infectious Diseases of Poverty is an open access, peer-reviewed journal that focuses on addressing essential public health questions related to infectious diseases of poverty. The journal covers a wide range of topics including the biology of pathogens and vectors, diagnosis and detection, treatment and case management, epidemiology and modeling, zoonotic hosts and animal reservoirs, control strategies and implementation, new technologies and application. It also considers the transdisciplinary or multisectoral effects on health systems, ecohealth, environmental management, and innovative technology. The journal aims to identify and assess research and information gaps that hinder progress towards new interventions for public health problems in the developing world. Additionally, it provides a platform for discussing these issues to advance research and evidence building for improved public health interventions in poor settings.